German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as ...

Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg ...

Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

独製薬会社バイエルは９日、開発中の更年期障害治療薬エリンザネタントについて、乳がん患者、または乳がんのリスクが高い女性に対しても良好な結果が出たと発表した。年内にも発売が見込まれる同医薬品は、対象範囲が拡大することになる。

Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines and unprecedented lipid nanoparticle (LNP) delivery solutions for oncology and ...

Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Biocon’s subsidiary, Biocon Biologics Limited (BBL), has announced the completion of its first year as a fully integrated ...